Admedus (ASX: AHZ) is a junior diversified biotechnology company living in the shadows of great Australian medical success stories like Cochlear ( ASX: COH ), CSL ( ASX: CSL ) and Sirtex Medical ( ASX: SRX ). After falling 10% yesterday, the market has overlooked the increased likelihood of huge revenue growth in the next 5 years because of a very minor capital raising which will be used to drive its overseas sales teams. With a market capitalisation of only $138 million, Admedus presents itself as a high risk but also high reward investment opportunity.